Article Text

Download PDFPDF
Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests JPP receives research funding from ARCA biopharma, Boston Scientific, Gilead, Janssen Pharmaceuticals, ResMed and St Jude Medical and provides consulting to Amgen, Johnson & Johnson, Medtronic and Spectranetics.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles